Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Highland Long/Short Healthcare Fund Class A (HHCAX)

11.60
Net Asset Value
-0.09%
1 Day
+3.29%
Year-to-Date
Overall Morningstar Rating
Long-short equity
Style or Category
5.5
Sales Expenses
2.80%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks long-term capital appreciation. The fund seeks to achieve its investment objective by investing at least 80% of the value of its total assets (net assets plus any borrowings for investment purposes) under normal circumstances in securities of companies principally engaged in the design- development- production- sale- management or distribution of products- services or facilities used for or in connection with healthcare or medicine ("healthcare companies"). It is non-diversified.

Performance

1 month-2.44% 3 years-5.12%
3 months+5.55% 5 years+5.06%
1 year-3.33% Since inception+4.58%
Data through --

Peer Comparisonvs. Long-short equity

 HHCAXCategory
Performance 5-yr return+5.06%+5.71%
Expense ratio2.80%1.90%
Risk 5 year sharpe ratio0.340.76
Net assets$93.4M$304.6M
Average market cap$8.5B$40.0B
Average P/E21.717.4
Portfolio turnover964%964%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyHighland Funds
Fund manager & tenureMichael Gregory / 7 Years
Minimal initial investment$2,500.00
Minimum IRA investment$50.00

Holdings

Cash65.78%
U.S. stock25.68%
International stock4.82%
Other2.80%
Fixed income0.93%
Top 5 Sectors
Portfolio weighting
Healthcare 94.68%
Hardware 2.03%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Top 10 Holdings
Portfolio weighting
ANTM WellPoint6.42%
ABBV AbbVie5.64%
UNH UnitedHealth5.64%
NERV Minerva Neurosciences Inc5.49%
MTD Mettler-Toledo International Inc5.21%
-- 5.08%
XBI SPDR® S&P Biotech ETF4.02%
IBB iShares Nasdaq Biotechnology ETF3.79%
GILD Gilead Sciences2.83%
-- 2.80%